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Abstract
The HMT3522 progression series of human breast cells have been used to discover how tissue architecture,
microenvironment and signaling molecules affect breast cell growth and behaviors. However, much remains to be
elucidated about malignant and phenotypic reversion behaviors of the HMT3522-T4-2 cells of this series. We employed a
‘‘pan-cell-state’’ strategy, and analyzed jointly microarray profiles obtained from different state-specific cell populations from
this progression and reversion model of the breast cells using a tree-lineage multi-network inference algorithm, Treegl. We
found that different breast cell states contain distinct gene networks. The network specific to non-malignant HMT3522-S1
cells is dominated by genes involved in normal processes, whereas the T4-2-specific network is enriched with cancer-related
genes. The networks specific to various conditions of the reverted T4-2 cells are enriched with pathways suggestive of
compensatory effects, consistent with clinical data showing patient resistance to anticancer drugs. We validated the
findings using an external dataset, and showed that aberrant expression values of certain hubs in the identified networks
are associated with poor clinical outcomes. Thus, analysis of various reversion conditions (including non-reverted) of
HMT3522 cells using Treegl can be a good model system to study drug effects on breast cancer.
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Introduction
A major challenge in systems biology is to uncover dynamic
changes in cellular pathways that either respond to the changing
microenvironment of cells, or drive cellular transformation during
various biological processes such as cell cycle, differentiation, and
development. These changes may involve rewiring of transcrip-
tional regulatory circuitry or signal transduction pathways that
control cellular behaviors. Such information is of particular
importance for seeking a deep mechanistic understanding of
cellular responses to drug treatments in various diseases, offering a
more holistic view of both microscopic and macroscopic changes
in the cellular functional machinery than has been available from
traditional analyses which usually focus only on finding differential
markers or close-up analysis of changes in a handful of molecules
constituting parts of some selected pathways of interest.
Network-based differential analysis naturally requires the
availability of multiple networks each in principle corresponding
to a specific biological condition in question, that are then
topologically rewired across conditions [1]. However, most
existing computational techniques for reconstructing molecular
networks based on high-throughput data cannot capture such
dynamic aspects of the network topology; instead, they represent
the networks as an invariant graph. For example, it is common to
infer a single invariant gene network using microarray data
obtained from samples collected over time or multiple conditions.
More sophisticated methods such as a trace-back algorithm [1]
and DREM [2,3] do emphasize uncovering the dynamic changes
of a network over time using time series data, but limitations in
these algorithms allow only certain kinds of dynamic behaviors,
such as ‘‘active path’’ [1] or bifurcating sequence of transcriptional
activations [2]. Moreover, such methods are heuristic in nature
and do not offer statistical guarantees on the asymptotic
correctness of the inferred ‘‘transient’’ components in the network,
making the results difficult to withstand the harsh standard on
stability and robustness when sample quality and size become less
ideal, as we face in the analysis to be conducted in this paper.
Indeed, a number of in-depth investigations of disease models
have suggested that over the course of cellular transformation in
response to microenvironmental changes due to disease progres-
sion or drug-induced reversion, there may exist multiple under-
lying ‘‘themes’’ that determine each molecule’s function and
relationship with other molecules [4,5]. As a result, molecular
networks at each cellular stage are context-dependent and can
undergo systematic rewiring (Figure 1). For example, strong
evidence of alterations of various pathways have been reported in
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the HMT3522 progression series of breast cells when malignant
T4-2 cells were phenotypically reverted by various drugs, albeit
only manifested by a small number of well-known signaling
molecules as discussed below [6–8].
In this paper, we conduct an in-depth study of the structural
changes in the gene regulatory networks underlying each cell state
in both the non-reverted and the reverted HMT3522 progression
series of breast cells. The HMT3522 cells have been shown to be
an excellent model system for studying the roles of tissue
architecture, microenvironment and signaling molecules involved
in the nonmalignant and malignant growth and behaviors of
breast cells, including the potential of various factors to cause
phenotypic reversion of malignant cells to nonmalignant states.
These cells originated from a nonmalignant human breast
epithelial sample, HMT3522 [9,10]. HMT3522-S1_LBNL (S1)
cells are from early passages which are nonmalignant and
dependent on exogenous epidermal growth factor (EGF) to grow.
HMT3522-T4-2_LBNL (T4-2) cells were generated from S1 cells
by a multi-step process: 238 passages in medium without EGF
followed by transplantation into a mouse which generated a
tumor, and T4-2 cells were isolated from the serial passage of this
tumor; thus T4-2 cells are malignant and tumorigenic [10].
Interestingly, when cultured in three-dimensional (3D) laminin-
rich extracellular matrices (lrECM), S1 cells form polarized acinus
structures with a central lumen which resemble the terminal milk-
secreting alveolar units in normal breasts [6,11], whereas T4-2
cells form disorganized structures under the same conditions.
Signaling molecules such as EGFR, b1-integrin, PI3K, and
MAPK are overexpressed in T4-2 cells relative to their levels in
S1. Crosstalk between these molecules plays pivotal roles in
defining malignant behaviors of T4-2 cells, and downmodulation
of them causes phenotypic reversion of T4-2 cells into growth-
arrested, normal-looking cells (also called T4R cells later) which
form structures resembling S1 acini but often without the lumen
[8]. Other molecules, such as TACE or Rap1, have also been
shown to be important for reversion of T4-2 cells [12,13].
NFkappaB was identified as one of the transcriptional regulators
involved in disorganization of T4-2 cells [14]. Despite significant
efforts to delineate key signaling events responsible for phenotypic
reversion of these malignant breast cells, many questions remain.
For example, are T4-2 cells reverted by inhibitors of different
molecules intrinsically the same? What is involved in the
phenotypic reversion of T4-2 cells at the systems level other than
a few genes directly related to the signaling molecules mentioned
above?
One classical approach to address these questions is to identify
genes differentially expressed between different cell states. While
this can lead to some information about marginal effects of the
genes in a particular stage of cancer progression or reversion, it
cannot yield insight into the underlying regulatory mechanisms
that govern interaction of genes with one another to carry out
complex cellular processes. Instead, we propose a network-based
differential analysis, by reverse engineering gene regulatory
networks of various conditions of the breast cells to depict a fuller
picture of regulatory mechanisms of the cells.
Many methods, as reviewed in [15,16], have been proposed for
reconstructing gene networks using gene expression microarray
data. Most of them [17–19], however, rely on the statistical
assumption that the samples in question were independent and
identically distributed (i.i.d), and thus they either lead to
estimation of a single network by pooling data from all the
samples together, or lead to estimation of a network for each cell
state independently. Since the breast cells in this study came from
non-reverted HMT3522 cells as well as various conditions of the
reverted cells, the regulatory mechanisms in different cell states
can be significantly different; therefore, pooling data from different
cell states together to estimate one single network does not reveal
networks in their full depth. On the other hand, reconstructing a
network specific to each cell state independently of the other ones
can be statistically inaccurate due to a small sample size for each
cell state. Recently, time-varying network detection methods have
been proposed that allow information sharing across time and can
thus recover a sequence of networks even with small sample sizes
[20–23]. For example, Song et al. proposed a time-varying
dynamic Bayesian network method to estimate a chain of evolving
networks over time [22]. However, these methods estimate
networks that evolve as a chain of networks over time, not as a
series of networks shared by the tree-shaped phenotypic relation-
ships as shown in Figure 1.
Due to the unique challenges we encountered to reconstruct
networks that rewire over the tree-shaped phenotypic relation-
ships, we recently proposed Treegl [24], a network reconstruction
algorithm that can effectively and jointly recover rewiring
regulatory networks present in multiple related cell states. Our
approach can not only recover a distinct network for each cell state
and reveal sharp differences among networks for different cell
states, but also capture and leverage similarities of the networks in
the cell states nearby in the phenotypic tree, thereby leading to
more accurate estimation of gene interactions in small sample size
scenarios. This new angle of estimating networks can reveal
information that has not been mined in traditional analysis.
In this paper, we conduct an extensive network analysis of non-
reverted HMT3522 cells (normal S1 and malignant T4-2 cells) as
well as three different conditions of reverted T4-2 cells using gene
expression microarray data obtained from these cells. It is notable
that the same set of the gene expression data was first described
and used in our previous work published in [24], however, our
focus then was to report the novel methodology behind the Treegl
algorithm, but not a thorough biological analysis of the HMT3522
series of cells from which the gene expression data was generated.
In this current work, we focus more on the biological findings
Author Summary
The HMT3522 isogenic human breast cancer progression
series has been used to study the effect of various drugs
on the reversion of the breast cancer cells. Despite
significant efforts to delineate key signaling events
responsible for phenotypic reversion of the malignant
HMT3522-T4-2 (T4-2) breast cells in this series, many
questions remain. For example, what is involved in the
phenotypic reversion of T4-2 cells at the systems level? In
order to answer this question, we analyzed gene expres-
sion microarray data obtained from these cells using our
recently developed tree-evolving network inference algo-
rithm Treegl. We reconstructed cell-state-specific gene
networks using Treegl. Our functional analysis results show
that we can not only unravel cell-state specific information
characteristic of non-malignant HMT3522-S1 (S1) and
malignant T4-2 cells in the series, but can also provide
insight into the T4-2 cells reverted by various agents. We
found that the networks specific to various conditions of
the T4-2 reverted cells are all suggestive of compensatory
signaling effects, which, however, are mediated by
different signaling pathways to antagonize different drug
effects in the reverted cells. Our results demonstrate that
the HMT3522 system when analyzed with Treegl may
potentially become an effective tool for novel drug-target
discovery and identification.
Network Analysis of Breast Cancer Cells
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discovered by a more comprehensive network analysis of the data
using Treegl and other bioinformatics tools, and aim to provide
better biological insights and understandings of the various breast
cell states in the HMT3522 series.
In particular, we estimated the network specific to each cell state
using Treegl. Our results showed that while the S1-specific
network contains predominantly nonmalignant pathways, the T4-
specific network contains various cancer-related pathways, both
findings consistent with biological evidence [4]. Furthermore, we
found that the networks specific to various conditions of the T4-2
reverted cells are enriched with pathways suggestive of compen-
satory effects. In the T4-2 cells reverted by inhibition of either
EGFR or b1-integrin, signaling pathways downstream of EGFR
or b1-integrin, mainly via the PI3K-AKT-mTOR axis, are
upregulated. Similarly, in the T4-2 cells reverted by either PI3K
or MAPKK, we observed upregulation of the pathways both
upstream and downstream of PI3K. These results are supported
by clinical evidence showing patient resistance to the same anti-
breast cancer drugs as we used in the study. Moreover, the
compensatory signaling is also observed in the differential network
of the T4-2 cells reverted by MMPIs, which involves genes
participating in protein catabolic processes. Together, our findings
suggest a common resistance mechanism employed by breast
cancer cells to antagonize drug effects. Finally, in order to identify
potential novel drug targets, we also investigated hubs (i.e., genes
with high degrees, see details in Materials and Methods) in the
differential networks of the breast cells, and characterized
specifically three hubs (NEBL, HBEGF, and PAPD7) whose
aberrant expression values are linked with the worst survival
outcomes in the breast cancer patients to provide insight into their
functional significance on the growth and development of breast
cancer cells. Our data suggest that Treegl when applied to an
effective disease model system, such as the HMT3522 cells, may
potentially become an effective tool for elucidating disease
mechanism and discovering novel drug targets, and thus help
make personalized medicine possible.
Results
We model a gene network as a Markov network [25], which is a
graph G~ V, Eð Þ where V is the set of vertices (genes), and E is
the set of edges. Genes u and v do not have an edge between them
if and only if they are conditionally independent given the values
of all other genes. We contrast this with a correlation network (a
common approach for modeling gene networks), in which u and v
are connected if their marginal pairwise correlation is greater than
a certain threshold. Correlation can be effective when analyzing a
pair of genes in isolation. However, when studying the dependence
Figure 1. A schematic representation of the relationship of the non-reverted and various conditions of the reverted HMT3522
breast cells. The nonmalignant S1 cell is the root of the tree. It is also the parent of the malignant T4-2 cell since T4-2 cells were derived from S1. The
T4-2 cells can be reverted to phenotypically normal-looking structures by treatment with various agents, such as: i) either EGFR or b1-integrin
inhibitor, ii) either PI3K or MAPKK inhibitor, or iii) MMP inhibitors, they are thus represented as the parent of the various conditions of the reverted T4-
2 cells. Microarray profiles were generated from each cell state represented in the tree, and gene networks specific to each state were reverse
engineered using Treegl.
doi:10.1371/journal.pcbi.1003713.g001
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between two genes in the context of other genes, correlation can
confound direct/indirect relationships, thus producing undesirable
results (Figure 2).
Specifically, we model the gene network for each cell state n as a
Gaussian Markov network. Gaussian distributions are special in
that the inverse of the covariance matrix, called the precision
matrix V nð Þ, completely encodes the structure of the Markov
network. In particular, an edge u,vð Þ exists in the Markov network
if and only if the corresponding precision matrix element is non-
zero.
Thus, under our model, the problem of learning the structure of
a gene network reduces to estimating V nð Þ. This is straightforward
when the number of genes p is smaller than that of microarray
samples S: one can compute the sample covariance matrix and
simply get its inverse. However, in high dimensional settings, when
p&S (as is our case), the sample covariance matrix is not
invertible, and thus the problem becomes substantially more
challenging. A statistically principled solution is the graphical lasso
[26], which estimates the neighborhood of gene u by using
regularized regression. The regression coefficients can be inter-
preted as estimates of the precision matrix elements up to a
proportionality constant (see Materials and Methods for more
details). After the neighborhood of each gene is estimated
independently, the results are combined to form a network.
Tree-evolving network detection algorithm, Treegl
However, our goal is not estimate a single network, but rather a
collection of networks, one for each cell state. One simple solution
is to estimate the network for each state independently of the
others using the graphical lasso. However, this approach can result
in poor quality of the networks due to the small sample size per cell
state. To overcome this challenge, our recently proposed
algorithm, Treegl [24], utilizes the following strategy. Similar to
the graphical lasso [26,27], Treegl estimates the neighborhood of
each gene independently of those of other genes using regularized
regression. However, unlike previous methods learning only a
single network, Treegl simultaneously estimates neighborhoods of
a gene in multiple networks each corresponding to a unique state
in the phenotypic tree of the breast cells. It is unique in that Treegl
makes use of a total variation regularizer based on the progression
and reversal relationships between pairs of cell states in question to
bias the amount of topological differences between networks
underlying the related states, and to allow information regarding
probabilistic independencies between genes to propagate across all
states either directly or indirectly related by phenotypes. Such a
strategy can lead to highly statistically confident estimation of a
gene Markov network [28], even under small sample size
scenarios. In the Materials and Methods section, we will offer
details of a novel statistical regularization technique that makes
this possible.
From the theoretical standpoint, Treegl is an instance of the
general varying coefficient varying structure (VCVS) formalism
analyzed in [29]. The VCVS model encodes changing structures
of gene networks in different cell states as a function of regression
coefficients in regularized regression problems. Estimating these
regression coefficients, and thus the associated network structures
then reduces to solving a convex optimization problem jointly over
Figure 2. An example demonstrating the difference between a Markov network and a correlation network. (A) A true network, in which
R is the regulator of A, B, and C. (B) A clique graph produced by a correlation network. Since all the genes in (A) are correlated with one another, the
correlation network cannot distinguish between indirect and direct relationships and thus connects all the nodes. (C) A correct graph recovered by a
Markov network. The Markov network recovers true relationship of the nodes because it uses conditional independence to determine the presence of
an edge.
doi:10.1371/journal.pcbi.1003713.g002
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all cell states. The global optimal solution for such a problem can
be found using standard convex solvers.
Moreover, the VCVS formalism allows one to theoretically
examine and prove the statistical conditions under which changes
in structures can be correctly estimated even in the high
dimensional setting when p&S. This distinguishes our approach
from other methods [17,30] that are highly non-convex and
therefore rely on local search heuristics that only find local optima.
These existing methods also do not offer sound statistical
machinery for addressing difficult conditions such as nonstatio-
narity (e.g., time-evolving) and high-dimensionality under small
sample size as we encountered in our study.
Having a theoretical framework allows us to trade-off model
expressivity and learning complexity in a principled manner. For
example, if we allow a complex and arbitrary network model (i.e.,
a dense network), then there would be no guarantees on the
quality of the recovered network structure in small-sample size
scenarios. Instead, by enforcing a restricted model (i.e., a sparse
network), its likelihood function is by definition convex and an
optimal solution may be found. Thus, the quality of the resulting
solution can be theoretically characterized, and it can be
determined under which conditions the correct underlying
parameters (network structure in this case) are discovered.
Fortunately, sparsity is also biologically justifiable. For example,
it is common to find a transcription factor regulating a limited
number of genes under specific conditions [31].
Simulation results
We first evaluate Treegl’s performance on simulated microarray
data. In order to find out how effectively Treegl can detect change
points of multiple networks while sharing information among
related cell states at the same time, we design the simulated
networks as illustrated in Figure S1. In particular, for each
experiment, an artificial collection of 70 networks related by a
tree-shaped lineage are generated, in which a sequence of 10
identical networks is connected to a network of different topology
via a change/branching point (see details in Materials and
Methods). Then, a small number of samples are generated from
each of the networks. It is important to note that Treegl does not
know a priori which of the networks are identical and which are
different and thus has to discover this based on the samples.
In order to evaluate how well Treegl can recover the underlying
network structures for the samples in the simulation data, we
compare Treegl with the static method estimating a single network
and the method estimating each network independently by
plotting the precision-recall curves which show the recall for
different values of precision based on the network estimated by the
three methods. As illustrated in Figures 3 & S2, Treegl performs
favorably to the other two methods. It should also be noted that
compared to the static method which produces only one network,
Treegl can produce different networks related by the tree lineage.
The independent method also produces different networks but it
performs poorly compared to Treegl.
A phenotypic tree representation of the HMT3522 series
of the breast cells
In order to reverse engineer gene networks of the breast cells,
we first used a phenotypic tree to represent the relationships of the
cells (Figure 1). Due to the small sample size of the microarray data
and imbalance of the sample abundance for different cell states
(see Materials and Methods for details) — both of the problems
pose significant challenges to network reconstruction — we used
what is known of the interrelatedness of signaling pathways
affecting phenotypic reversion to pool data derived from various
samples in order to increase the power of the network inference. In
particular, since EGFR and b1-integrin are cross-modulated in the
HMT3522 cells [8], we assumed that the gene networks in the T4-
2 cells reverted by inhibiting either of the molecules share
reasonable similarity, and hence we grouped data from these
reverted cells together to form the EGFR/ITGB1-T4R group.
Likewise, we grouped together data from T4-2 cells reverted by
either a PI3K inhibitor, a MAPK inhibitor, or a dominant-
negative Rap1 to form the PI3K/MAPKK-T4R group, because
PI3K and MAPK are also cross-modulated in the breast cells and
Rap1 signals through PI3K. A tree diagram illustrating the
relationships of the cells are shown in Figure 1. Based on these
relationships, we reverse engineered gene networks for the
HMT3522 cells using Treegl.
It is important to point out that it would be nearly statistically
impossible to reconstruct a cell-state-specific gene network using
existing methodology based on three microarray samples per
group as in the dataset we used here. Note that we will also refer to
different groups of the cells in the phenotypic tree in Figure 1 as
different cell conditions or states.
The reconstructed gene networks for the HMT3522 cells
The reconstructed networks for non-reverted and various
conditions of the reverted HMT3522 cells are illustrated in Figure
S3. They share many topological similarities as well as differences.
About 60% of the network edges are common to all cell conditions
represented in the phenotypic tree diagram, consistent with
underlying biological similarities shared between them. In the
following, we concentrate on only the edges specific to each cell
state, which we call the differential network for each cell state.
S1 differential network. Our pathway and GO analysis
showed that genes in the S1 differential network are significantly
enriched with those involved in normal cellular processes, such as
cell cycle, TCA cycle, and cellular respiration (Figure 4A, Tables
S1A & S2A). Notably, genes involved in tube lumen formation are
enriched only in S1 cells (Table S2A) while absent in the other cell
states, consistent with the observation that a central lumen is
always present in the acinus structure formed by S1 cells but often
absent from spheres formed by reverted T4-2 cells. Furthermore,
our disease relevance analysis did not find association of the genes
in the S1 differential network with any disease (Table S3A).
Together, these results agree with the biological fact that S1 cells
are nonmalignant.
T4-2 differential network. The T4-2 differential network,
on the other hand, is significantly enriched with genes involved in
a number of pathways important for tumor growth and
progression, such as ErbB and MAPK signaling pathways,
ECM-receptor interaction, and regulation of actin cytoskeleton
pathways (Figure 4B, Table S1B). Moreover, disease relevance
analysis showed that genes in the T4-2 differential network are
associated with various cancers, such as small cell lung cancer,
renal cell carcinoma, colorectal cancer, among others (Figure 5B,
Table S3B), and that genes involved in the pathways such as ErbB
and MAPK signaling pathways, focal adhesion, and ECM-
receptor interaction (Table S1B) have significant association with
pathways in cancer (FDR adjusted p-values,0.1). These data are
supported by biological evidence showing that ErbB and MAPK
signaling pathways, microenvironment, and integrity of tissue
architecture play significant roles in the malignant T4-2 cells [4,6–
8]. Together, these functional results suggest that Treegl can
indeed reveal biological characteristic that is specific to the states
in the HMT3522 cells.
Differential networks of the three conditions of the
reverted T4-2 cells. In order to find out whether T4-2 cells
Network Analysis of Breast Cancer Cells
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reverted by various agents are merely phenotypically or intrinsi-
cally normal, and also whether these different conditions of the
reverted cells are identical to one another at the systems level, we
examined the differential networks specific to each condition of the
reverted T4-2 cells.
EGFR/ITGB1-T4R differential network. Our pathway
analysis suggests that there are no pathways significantly enriched
in the differential network for this group of the cells (Table S1C).
However, a close examination of the enriched pathways (unad-
justed p values,0.05) revealed that genes involved in the pathways
downstream of EGFR, such as phosphatidylinositol and mTOR
pathways are enriched (Figure 4C, Tables S1C & S2C). Since
PI3K is a component of the phosphatidylinositol pathway, the
enrichment of the pathway suggests upmodulation of PI3K in
these cells (Figure S4). This is confirmed by the results showing
PIK3R2 (encoding a regulatory subunit of PI3K) and AKT1, but
not mTOR itself, are among the genes upmodulated in the
enriched mTOR pathway (Figure S5). Together, these results
suggest PI3K-AKT-mTOR signaling is activated in the EGFR/
ITGB1-T4R cells. Further, genes in the EGFR/ITGB1-T4R
differential network are connected with various cancers, including
prostate, and small cell lung cancer (Figure 5C, Table S3C),
Figure 3. Simulation results comparing the performance of Treegl to a method estimating a single static network and a method
estimating each network independently. In all cases, 70 networks were generated that are related by a tree lineage (See Materials and Methods
for details). (A) Each network has 30 nodes and 5 samples. (B) Each network has 30 nodes and 10 samples. (C) Each network has 50 nodes and 5
samples. (D) Each network has 50 nodes and 10 samples. In all cases, Treegl (shown in blue) performs favorably to the method estimating a single
static network (red) or the method estimating each network independently (green).
doi:10.1371/journal.pcbi.1003713.g003
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suggesting that despite phenotypic reversion to normal, some
malignant genes remain active in the EGFR/ITGB1-T4R cells.
Interestingly, activation of PI3K-AKT-mTOR signaling in our
data agrees well with clinical evidence showing that some breast
cancer patients develop drug resistance after being treated
with EGFR inhibitors, and that compensatory signaling via the
PI3K-AKT-mTOR pathway has been implicated in such resis-
tance [32–34]. Furthermore, our data suggest that mTOR
signaling is not mediated directly by mTOR, but rather by other
genes in the mTOR pathway, because mTOR per se is not
involved in the differential network of this condition of the
reverted cells; multiple other genes in the pathway, however, are
Figure 4. Illustration of selected enriched pathways in the differential network of each breast cell state. (A) S1; (B) T4; (C) the EGFR/
ITGB1-T4R group; (D) the PI3K/MAPKK-T4R group; and (E) the MMP-T4R group. In each plot, the differential network for the corresponding cell state is
shown. Nodes represent genes; edges represent interaction of the genes. Selected pathways enriched in the network (unadjusted p-values,0.05) are
color-coded and shown on the right; genes participating in the selected pathways are also colored based on the color code for the corresponding
pathway. An asterisk indicates a pathway that is significantly enriched in the corresponding differential network. The pathway names are shortened
to save space. See Table S1 for detailed information about the enriched pathways in each cell state.
doi:10.1371/journal.pcbi.1003713.g004
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upregulated. These results also agree with previous evidence in the
literature; despite a close link between mTOR signaling and
cancer, overexpression of mTOR has not been reported in human
tumors; instead, signaling events related to mTOR occur
frequently [35]. Our results may thus identify genes directly
involved in such drug resistance.
PI3K/MAPKK-T4R differential network. As expected, the
enrichment of the PI3K-related pathways is absent in the
differential network of the PI3K/MAPKK-T4R group of the
reverted cells due to the blockage of intracellular signaling
(Figure 4D). Our data, however, show that pathways both
upstream (insulin pathway) and downstream (mTOR pathway)
Figure 5. Diseases associated with the genes in the differential network of each breast cell state. (A) S1; (B) T4; (C) the EGFR/ITGB1-T4R
group; (D) the PI3K/MAPKK-T4R group; and (E) the MMP-T4R group. In each plot, the differential network for the corresponding cell state is shown.
Nodes represent genes; edges represent interaction of the genes. Diseases associated with the genes in the network (unadjusted p-values,0.05) are
color-coded and shown on the right; genes associated with a certain disease are also colored based on the color code for the corresponding disease.
An asterisk indicates a disease that is significantly enriched in the corresponding differential network.
doi:10.1371/journal.pcbi.1003713.g005
Network Analysis of Breast Cancer Cells
PLOS Computational Biology | www.ploscompbiol.org 8 July 2014 | Volume 10 | Issue 7 | e1003713
of PI3K are enriched (unadjusted p-values,0.05, Table S1D,
Figures S6 & S5), suggesting activation of compensatory signaling
due to the loss of PI3K signaling in the cells. Moreover, genes in
the differential network, particularly those involved in the
pathways such as mTOR, insulin, and apoptotic signaling, showed
association with cancer (Figure 5D, Table S3D). Even though the
p-values of the pathways are not significant after the FDR
adjustment, these results agree with recent clinical findings that
some breast cancer patients exhibit resistance to treatment by
PI3K inhibitors, and that mTOR and insulin growth factor (IGF)
signaling pathways have been implicated for such resistance [34].
However, no genes in these pathways have been identified for this
resistance yet. A close connection between insulin and IGF
pathways can be seen in Figure S5.
MMP-T4R differential network. Unlike the differential
networks in the other phenotypic reversion conditions mentioned
above, the MMP-T4R differential network has far fewer edges,
suggesting that fewer biological processes take place in the MMP-
T4R group of the reverted cells. Functional pathway and GO
analysis revealed that genes involved in protein catabolic processes
and transfer, such as ubiquitin-dependent and proteasomal protein
catabolic processes and receptor-mediated endocytosis, are signif-
icantly enriched (FDR p-values,0.05, Figure 4E, Tables S1E &
S2E). Interestingly, MMPs are known to play key roles in protein
catabolic processes, these results, therefore, suggest that when
MMPs are inhibited in T4-2 cells, genes participating in protein
catabolic processes and transfer are upregulated as compensatory
pathways to make up for the loss of the MMP function. Since
protein catabolic processes have been implicated in tumor
development [36], our data suggest the MMP-T4R cells still
possess tumor-developing potentials, consistent with clinical data
showing MMP inhibitors (MMPIs) delivered disappointing results
as anticancer treatments in clinical trials [37,38]. Furthermore,
disease relevance analysis showed that some pathways, such as
oxidative phosphorylation and metabolic pathways, in the MMP-
T4R differential network are significantly associated with diseases,
such as Alzheimer’s and Parkinson’s diseases (Figure 5E, Table
S3E). This suggests that despite being not as malignant as T4-2
cells, the MMP-T4R group of the reverted cells are not
intrinsically normal.
Survival analysis of hubs
In order to validate our network reconstruction results, we used
an external microarray dataset. Since previous evidence suggests
that there is a high correlation between the degrees and essentiality
of genes in yeast networks, we hypothesize that i) if a gene is
indeed involved in the networks of the breast cells, its abnormal
expression would have higher impact on the survival of breast
cancer patients than those genes which are not in the networks;
and ii) if a gene is a hub (with a high degree) in the differential
networks of breast cells, its abnormal expression would have
higher impact on the survival of breast cancer patients than those
with low degrees. We therefore investigated the effect of the
aberrant expression values of the hubs in the differential networks
of the HMT3522 cells on the survival of human breast cancer
patients. The external dataset we used is a gene expression
microarray dataset obtained from 295 primary human breast
tumors [39], employed previously to identify gene expression
signatures which may be predictive of patient clinical outcomes.
The same dataset was also used previously [12] to demonstrate the
impact of abnormal expression of TACE, TGFA, and AREG,
which were shown to play important roles in the HMT3522 series
of the breast cancer cells grown in the 3D culture, on the survival
of the same cohort of the breast cancer patients.
In order to define hubs, we examined the distribution of genes
with varying degrees in the differential networks. Figure S7 shows
that while a majority of the genes have degrees of 1–3, much fewer
genes have a degree greater than 5, and therefore, we designated
hubs to be genes with degree greater than 5 in the differential
networks. Note that the same criterion was also used to define hubs
in [40].
Indeed, we found that 18% of the genes in the networks of the
five breast cell states affect patient survival significantly, whereas
that only 6% of the genes which are not in the breast cell networks
but are present in the external dataset affect patient survival
significantly. Our results also showed that 22% of the hubs in the
differential networks of the breast cells affect patient survival
significantly. GO analysis revealed that these significant hubs are
enriched with genes involved in regulation of cell migration,
mobility, growth, and proliferation (see Table S4 for a list of the
hubs), and all of these biological activities are known to be essential
for cancer cell development and progression. Similarly, 23% of the
genes with degree .10 and also with degree .20 affect patient
survival significantly. However, for genes with degrees equal to
one to five in the differential networks, the percentage of them
affecting patient survival drops to 17%. Together, these results
indicate that i) genes in the breast cell networks indeed have higher
tendency of influencing patient survival significantly than those not
in the networks, and also that ii) hubs in the differential networks
are more likely to affect patient survival significantly than those
with low degrees, suggesting the structures of the reconstructed
networks are valid.
Neighborhood analysis of the hubs significantly affecting
patient survival
In order to identify potential novel drug targets, we examined
three hubs, NEBL, HBEGF, and PAPD7, whose extreme (i.e.,
either lower or higher) expression values are correlated with the
lowest 15-year patient survival rates (35%, 30% and 34%,
respectively) and also with low 10-year survival rates (60%, 42%
and 56%, respectively) in the examined dataset (Figure 6).
Previous evidence has shown that abnormal expression of TACE,
TGFA, and AREG are associated with 62%, 61% and 54% of the
10-year survival rates respectively, and associated with 57%, 50%
and 54% of the 15-year survival rates respectively, in the same
cohort of the patients [12]. Our results, therefore, suggest that
NEBL, HBEGF, and PAPD7, similar to TACE, TGFA, and
AREG, also play important roles in breast cells.
Since little is known about NEBL, HBEGF, and PAPD7, we
examined their neighbors in the corresponding differential
networks (which we call neighborhood analysis) to shed light on
their functions in breast cancer.
Figure 7A shows the NEBL subnetwork in the S1 differential
network. NEBL encodes a member of the nebulin family of
proteins, which bind actin and are components of focal adhesion
complex. Our data showed that decreased expression of NEBL is
associated with 36% of 15-year survival rate for breast cancer,
suggesting a protective role of this protein when overexpressed.
Genes interacting with NEBL in the NEBL subnetwork are mainly
involved in energy production by oxidation of organic compounds,
actin and cytoskeletal protein binding, regulation of growth, and
anatomical structure morphogenesis, all of which are consistent
with the biological evidence suggesting involvement of nebulin in
migratory cells [41].
Figure 7B shows the HBEGF subnetwork in the T4-2
differential network. HBEGF encodes a heparin-binding EGF-
like growth factor, which is an EGFR ligand [42]. We found that
higher expression of HBEGF is correlated with 34% of 15-year
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survival rate (Figure 6B), and that the neighbors of HBEGF in the
HBEGF subnetwork are involved in diverse biological processes
and functions, such as glycolysis, apoptosis, participating in
laminin-5 complex, notch signaling pathway, and angiogenesis,
all of which are in line with previous findings showing the high
expression level of HBEGF is positively related to the aggressive-
ness of the breast tumors [43] and that HBEGF plays key roles in
tumorigenicity and invasiveness of ovarian cancer [44].
Finally, we examined the PAPD7 subnetwork in the MMP-T4R
differential network (Figure 7C). PAPD7 encodes DNA polymer-
ase sigma. Our data indicated that overexpression of PAPD7 is
associated with 30% of 15-year survival rate and 8.5 years of
median survival time (Figure 6C), both of which are the worst
patient outcomes correlated with all the hubs in the differential
networks, suggesting that PAPD7 plays significant roles in breast
cancer cells. Previous evidence showed that a homolog of PAPD7
in Saccharomyces cerevisiae Trf4 plays a key role in RNA quality
control by degrading aberrant or unwanted RNAs in the nucleus
[45]. Interestingly, our functional analysis revealed that genes
interacting with PAPD7 in the MMP-T4R differential network are
significantly enriched with those involved in RNA degradation and
metabolic process, as well as regulation of Ras and small GTPase
mediated signal transduction, and phosphatidylinositol signaling
system (Figure 7C), which implicates that similar to Trf4, PAPD7
also participates in crucial functions such as RNA quality control
in human cells.
Taken together, these findings suggest that the three hubs,
NEBL, HBEGF, and PAPD7, in the differential networks play
important roles in growth and development of breast cancer cells,
and may thus become potential novel therapeutic targets. More
important, these results also suggest that our reconstructed
networks can not only reveal genes which have high impact on
patient survival in specific cell conditions, but also can provide
insight into their functions by neighborhood analysis, and thus
facilitate personalized drug target discovery and identification, and
help make personalized breast cancer therapy possible.
Figure 6. Kaplan–Meier curves estimating the association of different expression values of three hubs in the differential networks
of the breast cell states with survival of breast cancer patients. (A) NEBL in the S1 differential network; (B) HBEGF in the T4-2 differential
network; (C) PAPD7 in the MMP-T4R differential network.
doi:10.1371/journal.pcbi.1003713.g006
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Discussion
The problem of estimating rewiring networks simultaneously
from multiple cell states in the phenotypic tree, as solved by
Treegl, is fundamentally different from either estimating a single
‘‘average’’ network from the samples pooled from all states and
subsequently ‘‘trace-out’’ active subnetworks corresponding to
each state [1], or estimating multiple networks independently. The
latter strategies are common practices in the system biology
community, which either directly or indirectly assume the network
in question is static, and samples of the nodal states in the
phenotypic tree are i.i.d. across (when pooled) or within cell states.
Figure 7. Selected pathways or GO groups in the neighborhood of the three hubs in the differential networks of the breast cell
states. (A) NEBL in the S1 differential network; (B) HBEGF in the T4-2 differential network; and (C) PAPD7 in the MMP-T4R differential network. An
asterisk indicates a pathway or a GO group that is significantly enriched in the corresponding differential network.
doi:10.1371/journal.pcbi.1003713.g007
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In reality, such an assumption is biologically invalid as well as
statistically unsubstantiated. The Treegl algorithm elegantly
couples all the inference problems pertained to each network in
the tree of multiple conditions, and achieves a globally optimal and
statistically well behaving solution based on a principled VCVS
model and a convex optimization formulation.
In our analysis of the HMT3522 breast cancer cell lines, we
reverse engineered 5 different gene networks specific to each cell
state represented in the phenotypic tree. The S1 differential
network contains genes predominantly involved in normal cellular
activities, while the T4-2 differential network is enriched with
pathways playing active roles in cancers. Interestingly, compen-
satory signaling appears to be a recurring theme of the T4-2 cells
phenotypically reverted by different agents. In the T4-2 cells
reverted by inhibition of either EGFR or b1-integrin (i.e., the
EGFR/ITGB1-T4R group), despite the absence of the ErbB
pathway, signaling events downstream of EGFR or b1-integrin,
mainly via the PI3K-AKT-mTOR axis, seem to be upregulated.
These results are supported by clinical evidence showing that some
breast cancer patients exhibit drug resistance after being treated
with EGFR inhibitors. Similarly, in the PI3K/MAPKK-T4R cells,
their differential network is enriched with genes closely connected
to PI3K, suggesting they are upmodulated to make up for the loss
of PI3K signaling, also agreeing with clinical findings showing
patient resistance to PI3K inhibitors. Likewise, the compensatory
effect is observed in the differential network of the T4-2 cells
reverted by MMPIs, which involves genes participating in protein
catabolic processes presumably to make up for the loss of the
MMP function. The effect of MMPIs for treating breast cancer
patients was disappointing in clinical trials, but no conclusive
evidence for ineffectiveness has been put forward [38]. Our results
suggest that the failure of treating breast cancer patients by
MMPIs involves upmodulation of the catabolic processes in the
treated patients due to compensatory effect. Together, these results
suggest despite phenotypic similarities, T4-2 cells reverted by
various drugs are intrinsically different from one another; similar
compensatory mechanisms, however, appear to be utilized by the
T4-2 cells to antagonize effects of the different drugs.
In order to compare our network-based approach with
traditional statistical test-based approach, we also analyzed the
gene expression data using ANOVA, and identified 1432 genes
significantly differentially expressed (FDR p-value,0.05) across
different cell states; then we used pairwise t-tests to further identify
significant differences between cell states. We found that due to
small sample size problems, these traditional approaches are too
stringent to reveal interesting signals. For example, we examined
the genes differentially expressed between the T4-2 cells reverted
by MMP inhibitors (MMP-T4R) and other cell states, in
particularly between MMP-T4R and S1, as well as between
MMP-T4R and T4. Our results show that there are 473 genes
significantly differentially expressed in MMP-T4R, comparing to
S1, and the only two GO functional groups significantly enriched
(FDR p-value,0.05) among these genes are ‘‘mitotic cell cycle’’
and ‘‘sterol biosynthesis process.’’ Comparing to T4, there are 375
genes differentially expressed in MMP-T4R, and there are no GO
groups significantly enriched among these genes.
Moreover, we examined genes in the differential network of
MMP-T4R which are involved in some of the significantly
enriched GO groups, e.g., ‘‘proteasome complex’’ and ‘‘cellular
catabolic process’’, both of which suggest compensatory signaling
in the MMP-T4R cells. We found that among 12 genes in the
differential network of MMP-T4R (‘‘PSME3, PSMA4, PSMB8,
PSMD10, PSMA3, PSMB9, PSME2, PSMD7, PSMA6, PSMC2,
PSMA2, PSMD6’’) which are involved in ‘‘proteasome complex’’,
only two of them (PSMA3, PSMB9) significantly differ between
MMP-T4R and S1 as identified by ANOVA, and two (PSMC2,
PSMB9) significantly differ between MMP-T4R and T4. Likewise,
among 33 genes in the differential network of MMP-T4R which
are involved in ‘‘cellular catabolic process’’, only 5 genes
(‘‘PSMB9, ANAPC5, USP18, IDH1, PSMA3’’) significantly differ
between MMP-T4R and S1 as identified by ANOVA, and 3 genes
(‘‘PSMB9, USP18, IDH1’’) differ between MMP-T4R and T4.
Furthermore, we looked into the 22 hubs in the differential
networks which significantly affect patient survival, and found that
only 8 (36%) of them are differentially expressed across 5 cell states
as identified by ANOVA and a majority (64%) of them are not
differentially expressed. Similarly, among 99 hubs in the differen-
tial networks, 43% are differentially expressed, while 57% are not.
These results suggest that under small-sample-size scenarios,
traditional statistical tests are too stringent to capture interesting
signals, while our network-based differential analysis can leverage
on similarities among different samples while revealing key
differences which set them apart.
In order to identify potential novel drug targets, we also
investigated hubs in the breast cells whose aberrant expression
values are significantly associated with survival outcomes of breast
cancer patients. We found that genes in the networks of the breast
cells have 2 times higher tendency than those not in the networks
to affect patient survival in the cohort we studied. Also, hubs in the
breast networks appear more likely to influence patient survival
than genes with low degrees. Indeed, the proportion of the hubs
with high degrees which are significant survival genes (22% for
hubs with degree .5, and 23% for hubs with degree .10 and also
for those with degree .20) is not much higher than that (17%) of
the genes with low degrees. The reasons for this can be explained
as follows.
When previous evidence suggests that in yeast networks, a gene
with a higher degree is more likely to be an essential gene [46,47],
an essential gene is defined as ‘‘the cell is unviable when the gene is
knocked off’’ [47]. However, it is difficult to know/determine
which genes are essential in humans. Nevertheless, in light of the
definition of ‘essentiality’ in yeast, we think it is plausible to believe
that the actual percentage of the hubs (with degree .5) in the
differential networks of the breast cells, which can affect patients
significantly, is 22%+x%, rather than 22%, and the reasons why
we cannot see the phenotypic effect of the x% of the hubs on
patient survival may include: i) these hubs are so essential to
humans that any abnormality would lead to death, even before
breast tumors were formed or diagnosed; and/or ii) there are some
redundant genes which can make up for the loss/gain of functions
of these essential hubs.
Despite the fact that our results suggest that the genes in the
breast cell networks are more likely to affect patient survival than
those which are not, and also that hubs in the differential networks
tend to affect patient survival more than genes with low degrees,
our data show that the distributions of the patient survival rates (5-
year, 10-year or 15-years) associated with these different groups of
genes are not significantly different, suggesting that the patient
survival rates are not only affected by degrees of genes in the breast
cell networks, but also affected by the functionalities of the genes.
We have also characterized the three hubs in the cell-state-
specific differential networks whose aberrant expression values are
linked with the worst survival outcomes in the breast cancer
patients: NEBL in S1 cells, HBEGF in T4-2 cells, and PAPD7 in
the MMP-T4R group of the reverted cells. Our results are not
only in line with existing information known about these genes,
but also provide insight into their functional significance on the
growth and development of breast cancer cells. These hubs are
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promising to serve as potential drug targets for personalized breast
cancer therapy.
The major challenge of this work is the small sample size of the
microarray data we have used for the network inference. The data
was from 15 microarrays in total, and the T4-2 cells reverted by
different agents had to be pooled together in order to increase the
power of the network inference. Even though the sample grouping
strategy is biologically justifiable (see details in the Results section),
our abilities to find differences between T4-2 cells reverted by
different agents are limited due to mixed samples in the EGFR/
ITGB1-T4R and PI3K/MAPKK-T4R groups of the reversion
cells. For example, it is difficult to dissect which specific pathways
are abnormally regulated (compared to S1 cells) in which reversion
cell state: T4-2 reverted by EGFR inhibitors or by ITGB1
inhibitors. Likewise, it is also difficult to reveal differences in the
T4-2 cells reverted by different agents in the PI3K/MAPKK-T4R
group. Moreover, mixed samples can reduce power to detect
interesting signals in the data. Despite suggesting compensatory
events in the reversion cells, the enriched pathways in the EGFR/
ITGB1-T4R and the PI3K/MAPKK-T4R cells are not significant
(unadjusted p-values,0.05, but FDR p-values.0.1). However,
since our data agree well with clinical evidence, they may facilitate
clinicians to identify specific molecules which lead to resistance in
the drug-treated breast cancer patients. In order to overcome the
limitations of the mixed samples, we also focus on finding
similarities of the different T4-2 reversion cells. Our results show
that we were able to discover a significant amount of information
that agrees with the facts and evidence previously known in the
literature. Moreover, we were also able to delineate a mechanistic
framework at the systems level that can facilitate further
elucidation of the mechanisms underlying different states of the
breast cells in the progression and reversion model. Experimental
validations are nevertheless needed to further verify our findings.
In summary, this work demonstrates our recently developed
Treegl algorithm can not only provide a holistic view (i.e., the so-
called ‘‘pan-cell-state’’ view that echoes the emerging ‘‘pan-
cancer’’ or ‘‘pan-disease’’ approach nowadays to biomedical
analysis) of the progression and reversion model of the breast
cells worthy of further exploration, but also allows us to gain a
deeper and systems-level understanding about the behaviors of
nonmalignant and malignant breast cells, which may help novel
drug target discovery and make personalized breast cancer
therapy possible.
Materials and Methods
Cell culture and microarray hybridization
HMT3522 S1 and T4-2 cells were grown in 3D lrECM as
previously described [6,48]. The T4-2 cells were reverted using
each of the following reverting agents as described previously: an
EGFR inhibitor Tyrphostin AG 1478 and a human EGFR-
blocking monoclonal antibody mAb225 [7], a b1-integrin
inhibitor AIIB2 [6], a MAPK inhibitor PD98059 [7], a PI3K
inhibitor LY294002 [8], dominant-negative Rap1 [13]; an MMP
inhibitor GM6001 [49], and a broad-range inhibitor of MMPs
and ADAMs, TNF protease inhibitor–2 (TAPI-2) [12].
S1, T4-2 and reverted T4-2 cells were isolated from 3D cultures
with PBS/EDTA as previously described [50]. Total cellular RNA
was extracted using RNeasy Mini Kit with on column DNase
digestion (Qiagen). RNA was quantified by measuring optical
density at A260 and quality was verified by agarose gel
electrophoresis. Purified total cellular RNA was biotin labeled
and hybridized to the Affymetrix GeneChip human genome HG-
U133A arrays as previously described [51].
Gene expression microarray data and the sample
grouping strategy
Gene expression microarray data was obtained from 15 total
RNA samples prepared from the HMT3522 breast cells grown in
3D lrECM and treated with various reverting agents or vehicle
controls as mentioned above. Unfortunately, T4-2 cells reverted
by some agents have only one sample per each reversion cell state.
Even though our method, Treegl, is designed for small sample size
scenarios, having only one sample per state is not enough for
network inference — as it is known that it takes at least two
samples to measure even a simple quantity like correlation. Thus,
in order to increase the power of the network inference, we
grouped the arrays into the following five categories with each
having 3 samples: (i) S1 cells (3 arrays); (ii) T4-2 cells (3 arrays); (iii)
the EGFR/ITGB1-T4R group, which contains two arrays of the
T4-2 cells reverted by the EGFR inhibitor Tyrphostin AG 1478
and the human EGFR-blocking monoclonal antibody mAb225,
respectively, and one array of the T4-2 cells reverted by a b1-
integrin inhibitor AIIB2; vi) the PI3K/MAPKK-T4R group,
which contains one array of the T4-2 cells reverted by a MAPK
inhibitor PD98059, one array of the T4-2 cells reverted by a PI3K
inhibitor LY294002, and one array of the T4-2 cells reverted by
dominant-negative Rap1; and (v) the MMP-T4R group, which
contains two arrays of the T4-2 cells reverted by an MMP
inhibitor GM6001, and one array of the T4-2 cells reverted by a
broad-range inhibitor of MMPs and ADAMs, TAPI-2. The
biological justification on this grouping strategy is provided in the
Results section.
In order to identify networks specific to each state of the breast
cells, we utilized a phenotypic tree model to represent the
relationships of different states of the breast cells (Figure 1). In
particular, since the HMT3522 series were originated from S1
cells, we positioned S1 cells as the root of the phenotypic tree.
Then we made S1 cells the parent of T4-2 cells, since T4-2 cells
were derived from S1 cells. Finally, we made T4-2 cells the parent
of the three conditions of the T4-2 cells reverted by various agents
(the EGFR/ITGB1-T4R group, the PI3K/MAPKK-T4R group,
and the MMP-T4R group).
Microarray data preprocessing
Raw gene expression data was preprocessed using the following
procedure. The data from the perfect match (PM) probes on the
Affymetrix arrays was first log2-transformed, and normalized
using the CyclicLoess normalization method to minimize unwant-
ed noise in the data [52]. We did not use the difference between
the values from the PM probes and those from the mismatch
(MM) probes (i.e., PM – MM) to represent values of the probes for
each gene, because it has been shown that the MM values can pick
up both non-specific and specific signal of the probes, and thus
PM-MM values may attenuate real signal values from the PM
probes [53]. The normalized PM values were then summarized
into gene expression values using the median polish technique
[54]. For some transcripts, multiple probes on an array target the
same transcript; the values of the probes were combined by taking
the median of the values to represent the expression level of the
corresponding transcript. There are 12,977 unique genes on the
arrays. The complete microarray dataset is available at the Gene
Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.
gov/geo - GSE42125).
To reduce biological noise in the data, we removed genes whose
expression values showed low variability across different groups of
the breast cells. In particular, for each gene, we calculated its
median expression values in five different groups of the breast cell
states. If the fold change value of a gene between any of the two
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groups was larger than 1.3, we included the gene for the
downstream analysis. The reasons why we used the fold change
of 1.3 as the threshold value to filter genes are as follows: i) based
on our previous experience with human lung disease studies [55],
we found that a fold change of 1.2–1.3 is enough to elicit
significant biological changes in humans; and ii) When using the
threshold value of 1.3, 5,440 genes passed the filter, which we
consider is a reasonable number for the downstream network
analysis by Treegl. Then we applied Treegl to reconstruct gene
networks in the five breast cell states using expression values of the
qualified genes.
A mathematical representation of the gene networks for
the cell states in the phenotypic tree
We now give a mathematical formulation of representing the
gene networks in order to introduce our algorithm. Consider the
problem of modeling N different gene networks, each correspond-
ing to a unique cell state n. Each cell state n has Sn i.i.d.
microarray replicates. All the arrays in the dataset have the same
set of p genes. In our case, we have 5 different conditions of the
breast cells in the phenotypic tree: S1, T4, EGFR/ITGB1-T4R,
PI3K/MAPKK-T4R, and MMP-T4R.
As commonly done, we model each gene network as a weighted
undirected graph, where the vertices represent genes and the edges
represent interactions in the network. Let G nð Þ~ V , E nð Þ
 
represent a network in cell state n, where V denotes the set of
genes that is fixed for all cell states and E nð Þ denotes the set of
edges specific to the network for cell state n. Let
x n,sð Þ~ x n,sð Þ1 , . . . ,x
n,sð Þ
p
 
where s[ 1, . . . ,Snf g be the vector of
expression values of genes on array s in cell state n. We assume
x n,sð Þ*N 0,S nð Þ
 
, i.e. that the vector of expression values follows
a multivariate Gaussian distribution.
We are interested in reconstructing a set of networks
G 1ð Þ, . . . ,G Nð Þ that are related by the phenotypic tree as shown
in Figure 1. For each cell state n, let p nð Þ be the parent of the cell
state in the tree; alternatively, we can also view G nð Þ as a
descendant of Gp nð Þ. In our case, p S1ð Þ~NULL, p T4ð Þ~
S1, p EGFR=ITGB1{T4Rð Þ~p PI3K=MAPKK{T4Rð Þ~
p MMP{T4Rð Þ~T4. We generally let n~1 correspond to S1,
n~2 correspond to T4, and n~3{5 correspond to the EGFR/
ITGB1-T4R group, the PI3K/MAPKK-T4R group, and the
MMP-T4R group, respectively. Thus, in our formulation,
recovering the structures of the gene regulatory networks in
different breast cell states corresponds to estimating the network
structure for each cell state.
Estimating a gene network in a cell state
Consider first estimating the edge set of a single network G nð Þ
from the data. As described in the Results section, we model the
gene network for each cell state n as a Gaussian Markov network.
Therefore the inverse of the covariance matrix, called the
precision matrix, V nð Þ, completely encodes the structure of the
Markov network. An edge u,nð Þ exists in the Markov network if
and only if the corresponding precision matrix element is non-
zero.
A Gaussian Markov network, encoded via the precision matrix,
allows us to model more sophisticated dependencies than a
correlation network, which is encoded by the covariance matrix.
In particular, the precision matrix elements v
nð Þ
uv are related to the
partial correlation between u and v (denoted as r nð Þuv , see below for
details). Formally, partial correlation between a pair of random
variables u,vð Þ given a set Z of controlling variables is defined as
follows. Let Ru and Rv denote the residuals from performing linear
regression of u with Z and v with Z, respectively. The partial
correlation is then defined as the correlation between Ru and Rv.
Unlike correlation, which simply measures the association between
a pair of random variables, partial correlation intuitively measures
the association between a pair of variables with a set Z of
controlling variables removed (where here Z is all the other genes).
The partial correlation, due to its close relationship with the
elements of the precision matrix, makes the latter much more
suitable than the covariance matrix for distinguishing between
indirect and direct relationships as shown in Figure 2.
Since our goal is to learn the structure of the Markov network,
we are only concerned with estimating which precision matrix
elements are zero and which are not (rather than the exact
precision matrix values). Therefore it suffices to estimate the
partial correlation coefficients, which are proportional to the
precision matrix elements by the equation r
nð Þ
uv~
{v
nð Þ
uvffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
v
nð Þ
uu v
nð Þ
vv
q . An
estimation algorithm can be constructed by exploiting the
relationships between the partial correlation coefficients and a
linear regression model [56]. Specifically, consider a linear
regression model where gene u is treated as the response variable
and all the other genes are covariates. The regression coefficient
h nð Þuv of covariate v is then proportional to the partial correlation
r
nð Þ
uv .
The above facts enable us to use regression-based methods to
estimate the elements of the precision matrix (up to a proportion-
ality constant), and thus the underlying network structure. In
particular, our method is based on an efficient neighborhood
selection algorithm [26] based on ‘1-norm regularized regression
that works well in practice and has strong theoretical guarantees.
In this approach, the neighborhood of each gene u (the set of edges
incident to u) is estimated independently of the neighborhoods of
other genes. After estimating each neighborhood, the results are
then combined to produce the estimated network. In every
neighborhood estimation step, gene u is treated as a response
variable, and all the other genes are the covariates. An ‘1
penalized linear regression (also known as the lasso [57]) is
performed to give an estimate of the regression coefficients
h nð Þuv Vv[V\u.
Then by leveraging the relationship between the regression
coefficients and the partial correlation, the estimated gene network
G^ nð Þ is constructed by adding an edge u,vð Þ to G^ nð Þ if either h^ nð Þuv or
h^ nð Þvu is non-zero (max-symmetrization).
Estimating a tree-shaped genealogy of gene networks in
the breast cells
Obviously, networks for each cell state can be estimated
independently by using the method described above. However,
this can lead to very poor estimates of the edge sets, because in
common laboratory settings only a few replicates of gene
expression data can be obtained. To overcome this limitation,
we estimated the networks by assuming that the networks share
similarities due to their relationships as suggested by the
phenotypic tree, but also have some sharp differences. For
example, for S1 and T4-2 cells, we assume they have considerable
differences as the former is nonmalignant while the latter is
tumorigenic; however, since T4-2 were derived from S1, we also
assume that these cells share substantial similarity. This is the
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motivation behind Treegl, the algorithm that we first presented in
[24].
Treegl is unique in that it makes use of a total variation
regularizer, which allows information to be shared across
different cell states, and thus encourages the resulting networks
to be similar while allowing differences in the networks to be
revealed. More specifically, Treegl adopts the idea of neighbor-
hood selection and additionally penalizes the differences between
the neighborhoods of adjacent states in the breast cell phenotypic
tree. This makes Treegl more effective in small-sample-size
settings than existing approaches since it can estimate a collection
of networks more robustly by leveraging the similarities among
them.
In summary, Treegl proposes the following optimization
problem for jointly recovering the neighborhoods of genes for all
the cell states in the phenotypic tree of the breast cells:
h^
1ð Þ
\u , . . . ,h^
Nð Þ
\u ~
argmin
h
1ð Þ
\u
,...,h
Nð Þ
\u
XN
n~1
XSn
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In the equation above, the first term corresponds to the residual
sum of squares as in normal linear regression. x
n,sð Þ
\u indicates the
p{1 vector of the expression values of all genes except u, and
similarly, h
nð Þ
\u ~ h
nð Þ
uv : v[V\u
n o
. Sh(n)\u ,x
(n,s)
\u T is defined asX
v[V\u
h nð Þuv x
n,sð Þ
v . The second term (corresponding to l1) is a ‘1
penalty on the edge weights (similar to [26]), where zk k1 denotes
the ‘1 norm of vector z, which is the sum of the absolute values of
the components of z. This penalty promotes sparsity in the edge
weights by enforcing most of the edge weights to be zero. The
assumption of sparsity is biologically justifiable. For example, it is
common to find a transcription factor regulating a limited number
of genes under specific conditions [31]. The details of the ‘1
regularization can be seen in [57]. The third term (also called the
total variation penalty) associated with l2 enforces sparsity of
differences between S1 and T4-2 as well as between T4-2 and
each of the T4R groups (as illustrated in the tree structure in
Figure 1), but not between T4Rs and S1. This encourages many
(but not all) of the elements of h
nð Þ
\u to be identical to those of h
p nð Þ
\u .
The fourth term (also associated with l2) additionally penalizes the
differences between each of the T4R groups and S1, while
allowing for sharp differences to be revealed between the two
groups. Note that if the fourth term was not used, the T4R
networks would be biased to be more similar to the T4-2 network
than the S1 network. This would be undesirable, since it is
unknown a priori whether each of the T4R states are more similar
to T4-2 or S1 cells.
l1 and l2 are regularization parameters that control the amount
of penalization (see below for details on how we selected these
parameters). Because the minimization problem is convex, we
solved it using the CVX solver [58], as we described in [24].
In this work, we focus on genes linked by positive edges, because
interaction of these genes is easier to interpret. For example,
suppose genes X and Y are linked by positive edges, and genes Y
and Z are also linked by positive edges. Intuitively, this suggests
that genes X and Y are regulated in the same direction, that is,
when gene X is up (or down)-regulated, gene Y is also up (or
down)-regulated. Same is true for genes Y and Z which are also
regulated in the same direction. As a result, we can also decide that
genes X and Z are regulated in the same direction.
On the other hand, interpreting interaction of genes linked by
negative edges is more complicated. For example, suppose genes A
and B are linked by a negative edge and genes B and C also linked
by a negative edge. This intuitively means that A and B are
regulated in the opposite direction, and that B and C are also
regulated in the opposite direction; it is, however, unclear what is
the relationship of A and C, which may be regulated in either the
same or the opposite direction.
Due to the reasons stated above, we chose to limit the scope of
this work by focusing only on the positive edges to simplify our
interpretation of the results.
Selecting regularization parameters
Choosing the regularization parameters l1 and l2 is a
challenging problem in high dimensional statistics. Kolar and
Xing proposed to use the Bayesian information criterion (BIC)
score to select these parameters [59]. This approach can be useful
in low dimensional settings; however, it does not perform well in
high dimensional settings [60]. In this work, since we have a good
knowledge of the biological properties of the S1 and T4-2 cells in
the HTM3522 system, we employed a knowledge-based approach
to tune l1 and l2, namely, we tuned these parameters based on
our prior knowledge about S1 and T4-2 cells, which turned out to
be highly effective in the high dimensional, small sample size
setting as we encountered in this work. Specifically, we first varied
l1 and l2 in the set {4, 4.5, 5, 5.5, 6, 6.5, 7} and the set {0.5, 1,
1.5, 2, 2.5}, respectively, and generated cell-state-specific networks
for each possible pair of l1 and l2. These sets of l1 and l2 were
chosen because the networks can be generated with reasonable
sparsity. Then we examined the biological pathways significantly
enriched in the differential network of the S1 and T4-2 cells, and
found that when l1~4 and l2~2, almost all of the enriched
pathways in the T4-2 network make the best biological sense in
that they are either well described in previous studies or are known
pathways active in cancers. Since we used S1 and T4-2 cells to
help tune the regularization parameters, we present and discuss
mainly biological findings we made from the networks of the T4-2
reversion cells to avoid circular reasoning.
Synthetic network generation and evaluation
We describe below how the networks in our simulation
experiments were generated. Consider the following artificial
collection of 70 networks, related by a tree:
1) A network A with p nodes, with an average degree 4, and
maximum degree 6 is randomly generated. For the first 10
states, n~1{10, A remains unchanged, and thus, the
networks for cell states n~1{10 are identical.
2) After n~10, the network branches into two child networks, B
and C. To generate each child network, 25% of the edges are
randomly deleted and the same number of the edges are
randomly added. This represents a sharp, sparse change in the
network. These child networks remain unchanged for another
10 states (n~11{20 for B, n~21{30 for C).
3) B and C then branch (similar to step 2) to generate networks
D and E from B, and F and G from C. These networks
remain unchanged for another 10 states n~31{40 for D,
n~41{50 for E, n~51{60 for F, and n~61{70 for G.
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Treegl does not know a priori which networks are identical and
which are not. The number (S) of samples are then generated for
each network under the Gaussian Graphical Model assumption.
We vary the values of (p,S) in the simulation experiments, and the
results presented in Figures 3 are based on the values indicated in
the figure. In each scenario, the number of edges is twice as much
as the number of nodes.
To evaluate Treegl, we conduct a total of 10 simulation
experiments, and plot the precision-recall curves showing the
recall for different values of precision based on the networks
reconstructed by Treegl. The error bars in the curves indicate the
first and third quartiles of the results. Details on how we generated
the precision-recall curves and selected the regularization param-
eters can be found in [24].
Pathway analysis
To identify pathways significantly enriched in the gene networks
of the 5 breast cell states estimated by Treegl, we performed
pathway analysis on the list of the genes involved in each network
using the Category Bioconductor package with minor modification
(http://www.bioconductor.org). The Category package uses hy-
pergeometric tests to assess overrepresentation of the KEGG
pathways among genes of interest. A list of 12,977 unique genes on
the Affymetrix GeneChip Human Genome U133A was used as
the reference gene list for the pathway analysis. A pathway is
considered to be significant if p,0.1 with the FDR controlling
procedure of Benjamini & Hochberg [61].
Disease relevance analysis
To find out genes significantly associated with certain diseases
in the differential networks of the breast cell states, we performed
pathway analysis as described above. For each differential
network, pathways related to diseases and significantly enriched
in the network were singled out; genes in the network that are
involved in the enriched disease-related pathways were reported
as the genes significantly associated with the diseases in the
network.
GO analysis
To identify functional groups of genes significantly enriched in
the gene networks of the breast cells estimated by Treegl, we
performed GO analysis on the list of the genes involved in each
network using the GOstat program [62]. The GOstat program
finds the enriched functional groups using Fisher’s exact tests.
The GOstat program was also used to identify functional groups
of genes enriched among the neighborhoods (or the subnetworks)
of the hubs significantly affecting patient survival. A functional
group is considered to be significant if p,0.05 with the FDR
controlling procedure of Benjamini & Hochberg. A list of 12,977
unique genes on the Affymetrix GeneChip Human Genome
U133A was used as the reference gene list for the GOstat
program.
Survival analysis of hubs
We define hubs as genes with positive degree greater than 5
in the differential networks of the breast cell states. Survival
analysis was performed using microarray expression values of
the hubs extracted from a gene expression microarray data set
obtained from 295 primary human breast tumors [39]. For
each hub, its expression values across all patients were divided
into three groups: lower quartile, interquartile, and upper
quartile groups. Kaplan–Meier curves were used to estimate
the association of expression values of the hubs in the three
groups with patient survival. The log-rank test was used to
calculate p-values of the survival curves. A hub was considered
as significant if the p value of its associated survival curve ,
0.05 after controlling for multiple testing using the Bonferroni
procedure.
Supporting Information
Figure S1 Diagram depicting relationship of the networks in the
simulation experiment. Networks with the same color have an
identical network structure, i.e., networks 1–10 are identical,
networks 11–20 are identical, etc. The black solid lines represent
change-points where the network structure changes.
(EPS)
Figure S2 Precision-recall plots for each of the 70 individual
networks in the simulation experiment for 50 nodes, 10 samples
per network as shown in Figure 3D. Row 1 represents networks 1–
10, Row 2 represents networks 11–20, Row 3 represents networks
21–30, …, and Row 7 represents networks 61–70. Treegl is shown
in blue. The static approach of pooling all the samples to estimate
only one network is shown in red, while the results for estimating
each network independently without any information sharing is
shown in green. The scales of the x-axis and y-axis are identical to
those in Figure 3.
(EPS)
Figure S3 (Figure from [24]). An overview of the identified
cell-state-specific networks: (A) S1, (B) T4, (C) EGFR/ITGB1-
T4R, (D) PI3K/MAPKK-T4R, and (E) MMP-T4R. Only
edges of absolute weight .0.1 are shown. Hubs (i.e., nodes
with .5 edges) are in orange and enlarged proportional to
their degrees.
(EPS)
Figure S4 A KEGG diagram of the phosphatidylinositol
signaling pathway enriched in the differential network of the
EGFR/ITGB1-T4R cells. PI3K is identified by red arrows. Only
a section of the pathway is shown.
(EPS)
Figure S5 A KEGG diagram of the mTOR signaling pathway.
This pathway is enriched in the differential networks of both the
EGFR/ITGB1-T4R cells and the PI3K/MAPKK-T4R cells.
PI3K and mTOR are identified by red and blue arrows,
respectively. Insulin signaling pathway and INS/IGF are identified
by purple and pink arrows, respectively. Notice that IGF is
intimately connected with both insulin and mTOR pathways.
(EPS)
Figure S6 A KEGG diagram of the Insulin signaling pathway
enriched in the differential network of the PI3K/MAPKK-T4R
cells. PI3K, mTOR, and INS/IGF are identified by red, blue, and
pink arrows, respectively.
(EPS)
Figure S7 A plot showing the number of genes that have degree
d for various values of d. The plot in the inset displays the same
data, except that the y-axis is shown in log scale. The red arrow
points to the number of the genes with degree = 6. Since
comparing to genes with degree = 5, there is a noticeable
decreased number of genes with degree = 6, thus we designate
all the genes with degree .5 to be hubs.
(EPS)
Table S1 Significantly enriched pathways in the differential
networks of the breast cell states in the progression and reversion
model of the HMT3522 cells. (A) S1 differential network; (B) T4-2
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differential network; (C) EGFR/ITGB1-T4R differential network;
(D) PI3K/MAPKK-T4R differential network; (E) MMP-T4R
differential network.
(DOCX)
Table S2 Significantly enriched GO groups in the differential
networks of the breast cell states in the progression and reversion
model of the HMT3522 cells. (A) S1 differential network; (B) T4-2
differential network; (C) EGFR/ITGB1-T4R differential network;
(D) PI3K/MAPKK-T4R differential network; (E) MMP-T4R
differential network.
(DOCX)
Table S3 Diseases significantly associated with the genes in
the differential networks of the breast cell states in the
progression and reversion model of the HMT3522 cells. (A)
S1 differential network; (B) T4-2 differential network;
(C) EGFR/ITGB1-T4R differential network; (D) PI3K/
MAPKK-T4R differential network; (E) MMP-T4R differential
network.
(DOCX)
Table S4 Hubs in the differential networks of the breast cell
states significantly affecting survival of breast cancer patients.
(DOCX)
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